Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Results reflect different cardiovascular states in patients with types 1 and 2 diabetes

  1. Edmund J Lewis, principal investigator, Collaborative Study Group (Helen_Follmer@rush.edu)1,
  2. Collaborative Study Group
  1. 1Section of Nephrology, Rush University Medical Center, 1653 W Congress Parkway, Chicago, IL 60612, USA

    Editor—Verma and Strauss's editorial supports the contention that angiotensin receptor blockers are associated with increased risk of myocardial infarction.1 Included in the documentation of this risk are briefing documents from the US Food and Drug Administration quoting data from the irbesartan diabetic nephropathy trial.2 However, the authors did not cite our published analysis of cardiovascular events during this trial.3 Omitted was any mention that the difference …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular